SOUTH SAN FRANCISCO, California – March 5, 2026
SonoThera announced new preclinical research demonstrating the potential of its proprietary RIPPLE™ technology to deliver full-length dystrophin for the treatment of Duchenne Muscular Dystrophy (DMD). The data will be presented at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 taking place March 8–11 in Orlando, Florida. According to the company, RIPPLE™ (Remote Induction of Pulsed Pressure Lateral to Energy) is an ultrasound-mediated genetic medicine delivery platform designed to enable efficient, scalable, and nonviral delivery of large genetic payloads, including full-length dystrophin genes, across multiple muscle tissues. The findings highlight the platform’s ability to produce robust protein expression across skeletal, cardiac, and diaphragm muscles, offering a potential breakthrough in addressing key delivery challenges in gene therapy for DMD.
RIPPLE Technology Enables Nonviral Gene Delivery
A central challenge in developing effective gene therapies for Duchenne muscular dystrophy has been the efficient delivery of the full-length dystrophin gene, which is one of the largest genes in the human genome. Traditional viral delivery systems often face payload size limitations, immune responses, and challenges with repeat dosing, which can restrict long-term therapeutic effectiveness. SonoThera’s RIPPLE ultrasound-mediated delivery technology aims to overcome these barriers by using controlled acoustic energy to temporarily increase cell permeability, enabling genetic payloads to enter targeted tissues safely. In preclinical studies, RIPPLE demonstrated the ability to deliver genetic constructs encoding full-length human dystrophin, leading to meaningful protein expression in muscle tissues affected by DMD. Researchers observed broad biodistribution across skeletal muscles, heart tissue, and diaphragm muscles, which are critical targets for therapies intended to slow disease progression. The technology’s ability to deliver large genetic payloads without viral vectors could represent a major advance in the field of genetic medicine.
Preclinical Data Demonstrates Robust Expression Across Muscle Groups
The preclinical research presented by SonoThera evaluated the RIPPLE platform in multiple rodent and non-human primate models, providing early translational evidence supporting its potential clinical utility. The results demonstrated consistent and robust dystrophin protein expression across key muscle groups involved in Duchenne muscular dystrophy, indicating the platform’s ability to deliver therapeutic genes effectively throughout the body. Importantly, the studies showed that the delivery method is well-tolerated and capable of achieving targeted tissue distribution, helping ensure that therapeutic genes reach affected muscle cells where they are needed most. The platform also showed promise in maintaining durable expression levels while supporting repeat dosing, which could allow clinicians to administer additional treatments over time if necessary. These features address major limitations associated with viral gene therapies that may trigger immune responses or limit repeated treatment cycles. According to the company, the platform’s scalability and broad biodistribution capabilities position RIPPLE as a potential next-generation gene therapy delivery solution for neuromuscular diseases and other genetic disorders.
Advertisement
Ultrasound-Mediated Delivery Expands Future Genetic Medicine Potential
SonoThera’s technology uses ultrasound-mediated delivery (UMD) to enable precise targeting of tissues while minimizing systemic exposure and safety concerns associated with viral gene therapy platforms. By generating controlled pulsed pressure waves, RIPPLE temporarily alters cell membranes, allowing therapeutic genetic material to enter cells without permanent structural damage. This approach could enable safe, redosable, and cost-effective delivery of a wide range of genetic medicines, including DNA, RNA, and other advanced therapeutic payloads. The company believes the platform may support a pipeline of future therapies aimed at treating genetic disorders beyond Duchenne muscular dystrophy. Experts note that the ability to deliver full-length dystrophin using a nonviral and noninvasive approach could significantly improve treatment outcomes for DMD patients, as existing gene therapies often rely on truncated dystrophin versions due to viral vector size limitations. During the upcoming conference presentation, researchers will share additional details about RIPPLE’s performance and discuss how the technology may help advance next-generation gene replacement therapies for rare genetic diseases.
Duchenne muscular dystrophy is a severe genetic disorder characterized by progressive muscle degeneration caused by mutations in the dystrophin gene, leading to loss of muscle function and life-threatening cardiac and respiratory complications. Current therapeutic options remain limited, making the development of innovative gene delivery technologies a major priority in biomedical research. SonoThera’s RIPPLE platform represents a promising approach that could help overcome long-standing challenges in gene therapy delivery and enable the development of more effective treatments targeting the root causes of genetic diseases.
z
Source: SonoThera press release
